Modified intra-cerebral challenge assay for acellular pertussis vaccines: Comparisons among whole cell and acellular vaccines

Vaccine

Volumn 27, Issue 49, 2009, Pages 6824-6832

  Gaines Das, R ^a   Horiuchi, Y ^b   Zhang, S M ^c   Newland, P ^a   Kim, Y ^d   Corbel, M ^a   Xing, D ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^d Korea Food and Drug Administration   (South Korea)

Author keywords

Acellular pertussis vaccine; Protection model; Reference; Standards

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA VACCINE; PERTUSSIS VACCINE; TETANUS TOXOID;

ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CHINA; COMPARATIVE STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG FORMULATION; DRUG POTENCY; FREEZE DRYING; LABORATORY; MODIFIED INTRA CEREBRAL CHALLENGE ASSAY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RELIABILITY; STANDARD; WHOLE CELL; WORLD HEALTH ORGANIZATION;

ANIMALS; BIOLOGICAL ASSAY; LETHAL DOSE 50; MICE; MICE, INBRED ICR; PERTUSSIS VACCINE; REFERENCE STANDARDS; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 70350752288     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.014     Document Type: Article

References (25)

1. Ministry of Health and Welfare, Japanese Government. Minimum Requirements for Biological Products of Japan; 2006:146-9.
2. The Chinese pharmacopeia. 8th ed. (2005) pp. 67-71
3. Sato Y., and Sato H. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Tokai J Exp Clin Med Suppl. 13 (1988) 79-88
4. Kamiya H., and Nii R. Overview of currently available Japanese acellular pertussis vaccines and future problems. Tokai J Exp Clin Med Suppl. 13 (1988) 45-49
5. Isomura S. Clinical studies on efficacy and safety of acellular pertussis vaccine. Tokai J Exp Clin Med Suppl. 13 (1988) 39-43
6. Heininger U., Cherry J.D., Stehr K., Schmitt-Grohe S., Uberall M., Laussucq S., et al. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics 102 (1998) 546-553
7. Kato T., Kaku H., and Arimoto Y. Protection against pertussis by Takeda's acellular pertussis vaccine: household contact studies in Kawasaki City, Japan. Tokai J Exp Clin Med 13 Suppl. (1988) 35-38
8. Cherry J.D., Mortimer E.A., Hackell J.G., and Scott J.V. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Dev Biol Stand 73 (1991) 51-58
9. Heininger U., Stehr K., Christenson P., and Cherry J.D. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clin Infect Dis 28 (1999) 602-604
10. Xing DKL, Corbel MJ, Dobbelaer R, Knezevic I. WHO Working Group on standardisation and control of acellular pertussis vaccines-report of a meeting held on 16-17 March 2006. St. Albans, United Kingdom. Vaccine 2007;25:2749-57.
11. WHO Technical Report Series 897; WHO ECBS 49th Report; 2000.
12. Seagroatt V., and Sheffield F. A collaborative assay of the proposed second International Standard for Pertussis Vaccine and of the proposed first British Standard for Pertussis Vaccine. J Biol Standardization 9 (1981) 351-365
13. Xing D., Gaines Das R., Newland P., and Corbel M. Third International Standard for pertussis vaccine: International Confirmation Study of activity of British Standard for pertussis vaccine, coded 66/303. Biologicals 29 (2001) 133-136
14. WHO study report BS/88. 1586; 1988.
15. Kallings L.O., Olin P., Storsaeter J., and on behalf of the Ad hoc group for the study of Pertussis Vaccines. Placebo controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet 331 (1988) 955-960 8592
16. Finney D.J. Statistical method in biological assay (1978), Charles Griffin & Co.
17. Xing D., Gaines Das R., O'Neill T., Corbel M., Dellepiane N., Milstien J., et al. Laboratory testing of whole cell pertussis vaccine: a WHO proficiency study using the Kendrick test. Vaccine 20 (2002) 342-351
18. Redhead K., and Gaines Das R. A collaborative assay of the proposed Third British Reference Preparation for Pertussis vaccine and the relative potencies of the second International Standard and the second British Reference Preparation for Pertussis Vaccine. Biologicals 19 (1991) 107-111
19. Jansen D.L., and Meade B.D. Preparation and standardisation of US Standard Pertussis Vaccine Lot 11. Biologicals 24 (1996) 363-370
20. WHO study report BS/06.2036; 2006.
21. Aoyama T., Murase Y., Kato M., Iwai H., and Iwata T. Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age. Am J Dis Child Jun 143 June (6) (1989) 655-659
22. Isomura S., Suzuki S., and Sato Y. Clinical efficacy of the Japanese acellular pertuss vaccine after intrafamiliar exposure to pertussis patients. Dev Biol Stand 61 (1985) 531-537
23. Kato T., Goshima T., Nakajima N., Kaku H., Arimoto Y., and Hayashi F. Protection against pertussis by acellular pertussis vaccines (Takeda, Japan): household contact studies in Kawasaki City, Japan. Acta Paediatr Jpn 31 December (6) (1989) 698-701
24. Okada K., Ohashi Y., Matsuo F., Uno S., Soh M., and Nishima S. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study. Epidemiol Infect 137 January (1) (2009) 124-130
25. WHO Working Group on Acellular Pertussis Vaccines. WHO Working Group meeting on Standardization of Acellular Pertussis Vaccines: potency assay. Beijing, China, 7-9 November 2007. Vaccine 26 (2008) 3960-3968